Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MBP8298, LY2820671
dirucotide · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dirucotide | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| dirucotide | DRUG | 500mg, intravenous, every 6 months for 15 months |
| placebo | DRUG | intravenous, once every six months for 15 months |
Inclusion Criteria: 1. Male or female subjects, 18-50 years of age 2. Relapsing-remitting multiple sclerosis (RRMS) according to "Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria" (Annals of Neurology 58: 840-846) 3. At least 2 years history of MS before trial ent...
Dirucotide was studied for relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis, two forms of MS. It is a small molecule peptide developed by Eli Lilly and Company. Both Phase 2 trials in these indications have been completed, and no active trials are currently listed.
Dirucotide is a peptide, classified as a -tide, developed for multiple sclerosis. It is a small molecule modality. The supplied information identifies its target class as peptide but does not name a specific molecular target, so its precise mechanism of action is not described here.
Dirucotide is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 2 clinical program evaluating dirucotide in relapsing remitting and secondary progressive multiple sclerosis.
Dirucotide is in Phase 2 development. It has not been approved by the FDA and remains investigational. Two Phase 2 trials have been completed, one in relapsing remitting multiple sclerosis and one in secondary progressive multiple sclerosis, and no active trials are listed.
Dirucotide has been evaluated in two completed Phase 2 trials. NCT00869986 studied relapsing remitting multiple sclerosis with 218 participants across Bulgaria, Poland, Russia, Serbia, Slovakia, and Ukraine. NCT00869726 studied secondary progressive multiple sclerosis with 596 participants across Canada, Denmark, Estonia, Finland, Germany, Latvia, Netherlands, Spain, Sweden, and the United Kingdom.
Yes. The dirucotide Phase 2 program used randomized, double blind, placebo controlled designs. The relapsing remitting multiple sclerosis trial, NCT00869986, enrolled 218 participants, and the secondary progressive multiple sclerosis trial, NCT00869726, enrolled 596 participants. Both studies are completed and enrolled adults aged 18 years and older.